GLP-1 Drugs for MC4R Deficiency: Tirzepatide vs Semaglutide

THE PROTOHUMAN PERSPECTIVE#

This changes the calculus for roughly 6% of people with severe early-onset obesity who carry MC4R mutations — the single most common monogenic driver of excess weight. Until now, these individuals have been pharmacologically stranded. Setmelanotide, the only approved drug for POMC-LEPR deficiency, doesn't work for MC4R-null patients because it targets the very receptor that's broken. The finding that GLP-1 receptor agonists operate through MC4R-independent neural pathways means we're looking at a class of drugs that sidestep the genetic defect altogether. For the biohacking and longevity community, this has broader implications: it suggests that incretin-based therapies modulate energy homeostasis through redundant systems — not just the canonical leptin-melanocortin axis. That redundancy matters for anyone trying to understand why these drugs work as powerfully as they do, even in metabolically "broken" models.

THE SCIENCE#

What MC4R Deficiency Actually Means#

The melanocortin 4 receptor is a G-protein-coupled receptor sitting in the hypothalamus, functioning as a critical node in the POMC-MC4R and leptin-MC4R signaling cascades that regulate satiety, feeding behavior, and energy expenditure. When MC4R is knocked out — whether genetically in mice or through pathogenic loss-of-function variants in humans — the result is hyperphagia, reduced energy expenditure, and severe obesity from early childhood^[1][5].

This isn't lifestyle obesity. This is a broken thermostat.

The only approved pharmacotherapy for the broader POMC pathway, setmelanotide, is an MC4R agonist. Which means it's useless if the receptor itself is non-functional. That left MC4R-deficient patients with no targeted treatment — until GLP-1 analogs entered the picture.

The Mouse Model: Head-to-Head Comparison#

The study published in International Journal of Obesity by Yokoi and colleagues used MC4R knockout mice — animals completely lacking functional MC4R — and administered semaglutide, tirzepatide, and retatrutide for 21 days^[1]. The results were unambiguous:

• Semaglutide: 19.7 ± 4.1% body weight reduction
• Retatrutide: 24.1 ± 5.8% body weight reduction
• Tirzepatide: 31.6 ± 7.6% body weight reduction

Tirzepatide dominated. But here's where it gets more interesting than raw weight numbers.

All three analogs suppressed both fat mass and lean mass on Echo-MRI body composition analysis. They improved plasma insulin, HOMA-IR (a surrogate for insulin resistance), total cholesterol, and liver damage markers AST and ALT. Liver hypertrophy — a hallmark of NAFLD progression in these models — was reduced across the board^[1].

At the gene expression level, all three drugs downregulated fatty acid synthesis pathways. But none of them significantly altered inflammation-related gene expression. That's a notable gap. If you're expecting these drugs to resolve hepatic inflammation in the context of NASH progression, this preclinical data doesn't support that assumption — at least not in 21 days.

Only tirzepatide significantly decreased the respiratory quotient (RQ), indicating a metabolic shift toward greater fat oxidation relative to carbohydrate utilization^[1]. This aligns with tirzepatide's dual GIP/GLP-1 receptor agonism — the GIP receptor engagement appears to drive substrate partitioning in a way that pure GLP-1 agonism alone does not.

The Human Evidence: SURMOUNT-1 Reanalysis#

The preclinical data would be interesting but insufficient on its own. What elevates this story is the parallel human evidence published in Nature Medicine by Bhatnagar et al.^[3].

The researchers went back into the SURMOUNT-1 trial dataset — 2,291 participants with obesity — and genotyped them for MC4R pathogenic variants. They found 32 carriers (1.4% prevalence), consistent with known population estimates for MC4R loss-of-function mutations in severe obesity cohorts.

The key finding: MC4R mutation carriers on tirzepatide lost 18.3% of body weight over 72 weeks, compared to 19.9% in noncarriers. The weight loss trajectories were virtually superimposable^[3][4].

Let me be direct about why this matters. A 1.6 percentage point difference over 72 weeks, in a genetically disadvantaged subgroup, is clinically negligible. These patients, who were previously considered pharmacologically untreatable with anything except bariatric surgery, responded almost identically to people without the genetic defect.

The catch, though. Thirty-two carriers is a small number. The confidence intervals are wide enough that I'd want to see a dedicated trial — and two are currently underway (NCT06439277 and NCT06074667)^[5]. Until those report, I'm cautiously optimistic but not writing prescribing guidelines.

Real-World Performance: Tirzepatide vs. Semaglutide#

Separate from the MC4R question, a retrospective cohort study using Truveta de-identified US EHR data compared tirzepatide and semaglutide in 2,396 patients with obesity (without diabetes) over 6 months^[2].

Tirzepatide produced a mean weight reduction of −11.15% versus −8.83% for semaglutide — an adjusted difference of −2.32 percentage points (95% CI: −3.17, −1.48)^[2]. Higher proportions of tirzepatide patients hit every weight-reduction target: 5%, 10%, 15%, and 20%. Tirzepatide also showed greater reductions in BMI, blood pressure, and HbA1c.

I'm less convinced by one aspect of this study: it was funded by Eli Lilly, the manufacturer of tirzepatide. The data directionally aligns with the SURMOUNT-5 trial results, so there's no obvious red flag — but industry-funded retrospective analyses always deserve a raised eyebrow.

COMPARISON TABLE#

THE PROTOCOL#

For individuals with confirmed or suspected MC4R deficiency exploring GLP-1 analog therapy — this is not a self-prescribing guide. Work with an endocrinologist or obesity medicine specialist.

1. Get genotyped first. If you have severe obesity with childhood onset, family history of obesity, or hyperphagia that doesn't respond to standard interventions, request MC4R sequencing through a clinical genetics service or a research-grade panel. Prevalence of pathogenic MC4R variants in severe obesity populations runs 2–6%. Knowing your status changes the treatment conversation entirely.

2. Initiate with standard dose-escalation protocols. For tirzepatide, current clinical practice starts at 2.5 mg subcutaneous weekly, escalating by 2.5 mg every 4 weeks as tolerated, up to a maximum of 15 mg weekly. For semaglutide, start at 0.25 mg weekly, escalating to a target of 2.4 mg. The MC4R KO mouse data and SURMOUNT-1 human reanalysis suggest standard dosing is effective — there is no evidence that MC4R-deficient patients need higher doses^[1][3].

3. Monitor body composition, not just scale weight. All three GLP-1 analogs suppressed lean mass alongside fat mass in the preclinical model^[1]. Track lean mass via DEXA or bioimpedance every 8–12 weeks. If lean mass loss exceeds 30–40% of total weight lost, increase protein intake to ≥1.6 g/kg/day and add resistance training.

4. Track hepatic and metabolic markers at baseline, 3 months, and 6 months. The preclinical data shows improvements in AST, ALT, insulin, HOMA-IR, and cholesterol^[1]. Request a comprehensive metabolic panel plus liver enzymes. If you have known NAFLD/MAFLD, add hepatic ultrasound or FibroScan at baseline and 6 months.

5. Assess respiratory quotient shift if possible. For biohackers with access to metabolic cart testing or VO2 assessment, measure RQ before and after 8–12 weeks of treatment. The tirzepatide-specific RQ reduction in MC4R KO models suggests enhanced fat oxidation — a proxy for improved mitochondrial substrate flexibility. This is relevant if you're also stacking interventions that target mitochondrial efficiency (cold exposure, zone 2 training, NAD+ precursors).

6. Reassess at 6 months using the real-world benchmarks. Based on the Truveta cohort data, expect approximately 11% body weight reduction on tirzepatide or 9% on semaglutide at 6 months in a general obesity population^[2]. MC4R-deficient patients in the SURMOUNT-1 reanalysis tracked close to noncarriers, so these benchmarks should apply.

What is MC4R deficiency and how common is it?#

MC4R deficiency is the most common monogenic cause of obesity, caused by loss-of-function mutations in the melanocortin 4 receptor gene. It affects an estimated 2–6% of people with severe early-onset obesity. Carriers typically present with hyperphagia and progressive weight gain from childhood, driven by disrupted hypothalamic satiety signaling^[5].

Why don't existing MC4R-targeted drugs work for MC4R-deficient patients?#

Setmelanotide, the only approved MC4R agonist, works by activating the MC4R receptor directly. If the receptor itself is non-functional due to pathogenic mutations, the drug has no target to bind. GLP-1 analogs bypass this entirely by acting through GLP-1 (and GIP) receptors on separate neuronal populations in the arcuate nucleus^[1].

How does tirzepatide compare to semaglutide for weight loss?#

In MC4R knockout mice, tirzepatide produced 31.6% weight reduction versus 19.7% for semaglutide over 21 days^[1]. In real-world human data (general obesity, 6 months), tirzepatide showed −11.15% versus −8.83% for semaglutide^[2]. The dual GIP/GLP-1 mechanism appears to provide an additive metabolic advantage, particularly in shifting substrate oxidation toward fat.

When will retatrutide become available for clinical use?#

Retatrutide is still in clinical trials and has not received FDA approval as of early 2026. It showed 24.1% weight reduction in the MC4R KO mouse model — positioning it between semaglutide and tirzepatide^[1]. Phase 3 trial results are expected to inform regulatory submissions, but no approval timeline has been announced.

Who should consider genetic testing for MC4R variants?#

Anyone with severe obesity (BMI >40) with onset in childhood, persistent hyperphagia, and a strong family history of obesity should discuss MC4R sequencing with their physician. In the SURMOUNT-1 cohort, 1.4% of participants carried pathogenic MC4R variants — many likely undiagnosed previously^[3].

VERDICT#

8/10. The convergence of preclinical head-to-head data and a human genetic reanalysis from SURMOUNT-1 makes this one of the more compelling stories in precision obesity medicine right now. Tirzepatide's performance in MC4R-deficient models — both mouse and human — is striking, and the fact that it works through MC4R-independent pathways opens a treatment door that was previously locked. I'm docking points because the human MC4R carrier sample was small (n=32), the mouse study was 21 days (short for metabolic outcomes), and the real-world comparative study carries industry-funding bias. The signal is strong. The confirmation is still coming.